Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Monday, Monday
Can't trust that day
Yes please tryn2 ...
How did LP personally Dilute ?? Did she increase the number of discounted "C" shares ?
Another crappy week for s/h, two years since data lock!!!!!!
Data is so great Linda feels the need to dilute more shares below market!
The ceo that keeps on giving!
This NWBO back and forth makes me LOW... Laughing Out Wildly
good to see a huge family fund share their confidence and investment in NWBO!
Thanks for sharing Crash!
Billionaire Robert Hefner on NWBO:
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022
If no docs are prescribing the helmet that says quite a bit!
These are likely (hopeful)(fingers crossed)(we've said it before) (one day closer) chain of events. I laugh at myself thinking all this would have happened a year ago. Live and learn. Still holding and waiting
That doesn’t prove anything about doctors opinions
Hey thanks Hoff
Sounds good to me
listen to their quarterly on 10-27 and look at the low/stagnant numbers. that will be proof enough
Let us also not forget the Series C shares... created, I believe, for partnership. This is how I see the next few months going...
1. Peer Reviewed Journal Article
2. Commercial manufacturing approved in UK
3. Acceptance of Application to manufacture and sell DCVAX-L for Brain tumors in UK (MAA?)
4. Approval of said Application
5. $MRK buys all Series C shares for $2 Billion (or more) to partner with NWBO... common goes to >$8 instantly
6. NWBO uplists to either DOW or NASDAQ
7. Institutional buyers push pps over $20
8. $MRK buys NWBO for multiple of $20... maybe stock trade of 2 NWBO for 1 MRK...
We might see the price going up because we are close to approval, but you cannot call it a pump.
Hardly surprising as Dr Toms is a paid consultant by Novocure:-
Consultant or Advisory Role: Steven A. Toms, Medtronic (C), Novocure (C
https://ascopubs.org/doi/10.1200/jco.2013.53.2788
Right pgsd !
Well done, good to read ( especially for the non-believers).
Thanks.
if people want to wear the helmet for 18 hours a day and 21k per month and think they are getting a benefit from it I have no problem with that
Alrighty, the NYAS pump started early April and pushed the price from upper $0.60s to almost $1 prior to consolidating for a short stint prior to the big run up.
We're about at that time frame for SNO. Might we see a 25%+ week?
Hoff, and yet two of the first 3 top brain cancer physicians on the list you frequently post say favorable things about optune, Dr Toms in particular says he sees 5 year survivors with it
Fully agree with you Horse4CarT!
We will probably know a lot more before November 20th than we do now or the past (7) years in my case.
Good Luck to us longs and believers..
I (for one) trust her judgement as well as her colleagues. I personally think if there was not a huge void in treatment options at the time then it would be unlikely it would have been approved at all.
For anybody paying attention there are very good reasons why the trial has taken so long and why we have not had accelerated approval YET. What is evident is the importance the UK assigns to this technology as shown by their designations and recent approval (PIP). The 'writing is on the wall' with approval pending.
that's a good one!
So you’re saying that JP Morgan, Goldman and others don’t have specialists that understand what’s going on the science industry. That they’re not looking for the next game changer.
Not sure I get your point. Very few on this board may not understand but major investment firms sure do and I’m just surprised that they’re not following or buying.
Just my opinion.
When you combine the fact that our trial was adopted as a national priority trial in the UK, designated "A promising innovative medicine" (PIM), along with the filing of application for licence for commercial manufacturing and approval of Pediatric investigation plan by MHRA, IMO really not a question IF DCVax is approved by MHRA, only WHEN
2013 was 9 years ago so if DCVax-L was a priority for the UK I’d hate to see how long something that was not a priority would take.
The reason that these great sounding announcements get forgotten is that the passage of time reveals their truth worth and bringing them up again elicits embarrassment or annoyance.
Ironically this isn’t management’s fault.
Ultimately all these government shortcuts meant to expedite stuff for companies, patients or both like EAMS, HE, or Right to Try never amount to much.
Until you see what it means in terms of increases speed, on the ground you have to assume it’s fluff.
We’ll it’s been 9 years and the trial was well along in 2013 so the jury has come in:
This was fluff.
SALIENT RESEARCH :
pgsd
Re: None
Monday, October 03, 2022 2:20:43 AM
Post#
518586
of 518592
???? The Danish Dude ???? (Madam/Your highness)
@FlemmingBruce
$NWBO
What did Linda Liau say in an interview, 2 years ago?
Comment 1:
https://twitter.com/FlemmingBruce/status/1576557919042093057
DONE. Flaskworks has managed to do, what Liau means is lacking.
https://billmalloy.info/qa-with-linda-liau/
pgsd
Re: None
Monday, October 03, 2022 6:42:59 AM
Post#
518590
of 518593
Excellent post, in the passage of time some key and positive factors are forgot or overlooked.
NW Bio’s Phase III Trial With DCVax®-L For Brain Cancer “Adopted” As A National Priority Trial In UK
Cred54675419C's avatar
c red @Cred54675419C
1h
Replying to @TodosInvestor @FlemmingBruce @WayneLee1983
The UK government has set a goal of making the UK a world leading innovator in medicines.
FlemmingBruce's avatar
???? The Danish Dude ???? (Madam/Your highness)
@FlemmingBruce
Replying to @Cred54675419C @TodosInvestor @WayneLee1983
Great info @Cred54675419C ??
The NIHR maintains a “portfolio” of clinical trials that have
been “adopted” as high priorities for the UK. In order to be
selected for the NIHR Portfolio, a proposed clinical trial must go
through multiple layers of review and evaluation. The
evaluation includes the potential significance of the new medical
technology being tested, the quality of the trial design, the
feasibility of the trial, and numerous other factors.
Trials that are selected (“adopted”) for inclusion in the NIHR Portfolio are monitored closely by
the NIHR and the trial sites receive several types of financial and operational support. For
example, the NIHR provides resources and funding for additional staff (e.g., nurses) at the trial
sites to help accelerate the trial. The NIHR also oversees the performance of the sites, and
imposes penalties on the sites for shortfalls such as lags in enrollment.
“We understand that it is relatively rare for a small biotech company to have its clinical trial
‘adopted’ into the NIHR portfolio, especially a Phase III trial,” noted Linda Powers, CEO of NW
Bio. “This important validation of our trial is an exciting development, and the extra resources
and support from the NIHR to the trial sites will be very helpful in accelerating our trial.
https://nwbio.com/nw-bios-phase-iii-trial-with-dcvax-l-for-brain-cancer-adopted-as-a-national-priority-trial-in-uk-2/
SkyLimit2022
Re: dr_lowenstein post# 518567
Sunday, October 02, 2022 10:39:01 PM
Post#
518569
of 518593
Maybe you’re right—and maybe DCVax patients are paid to be alive too.
So many of these survivor stories are old news— research 2022 updates—some are GBM patients surpassing a decade or multiple decades—miraculous …
https://www.hawaii.edu/news/2017/03/30/newirth-laker-for-a-day/
https://m.youtube.com/watch?v=K9azZaIwOH8&feature=youtu.be
SkyLimit2022
Re: HyGro post# 518554
Sunday, October 02, 2022 9:54:46 PM
Post#
518560
of 518594
NVCR made some specific statements too in their February 24th 2022 SEC filing. Their risk disclosures start on page 26 of the NovoCure filing posted below. You stated that SEC filings are submitted under penalty of perjury and should be considered by investors. I tend to believe that the documents as a whole are important, but we could follow your lead and pluck out some interesting risk statements to publish in isolation. What do you think?
https://d18rn0p25nwr6d.cloudfront.net/CIK-0001645113/c5eca622-306f-417f-931b-c2ab018fa6b6.pdf#page25
SkyLimit2022
Re: HyGro post# 518556
Sunday, October 02, 2022 9:57:01 PM
Post#
518561
of 518594
Thank you for again again again reminding us about Pazdur’s position on this point:
https://www.annalsofoncology.org/article/S0923-7534(22)00006-0/fulltext
"Novel agents are so obviously superior to standard of care that no patient would participate in a randomized trial knowing that somebody else might get the experimental drug.”
—Richard Pazdur, MD
Richard Pazdur, M.D. is the director of the FDA's Oncology Center of Excellence (OCE), which leverages the combined skills of the FDA's regulatory scientists and reviewers with expertise in drugs, biologics and devices to expedite the development of novel cancer products. In his role as director of the OCE, Pazdur is responsible for leading the effort to develop and execute an integrated regulatory approach to enhance the cross-center coordination of oncology product clinical review.
Pazdur previously served as the director of the Office of Hematology and Oncology Products (OHOP) in the FDA’s Center for Drug Evaluation and Research and will continue to serve in OHOP as acting director. This Office was formed in 2005 to consolidate the review of drugs and therapeutic biologics for the diagnosis, treatment, and prevention of cancer, as well as the review of drugs and therapeutic biologics for hematologic diseases and for medical imaging. As director of OHOP, Pazdur facilitated coordination of oncology activities across all FDA Centers and ensured an ongoing outreach and collaboration between the FDA, the National Cancer Institute, and other cancer-related organizations within and outside of the government. Pazdur was the director of the Division of Oncology Drug Products from September 1999 to May 2005.
Prior to joining the FDA, Pazdur was professor of medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. Pazdur was on the faculty of the M. D. Anderson Cancer Center from 1988 to 1999. During his tenure at the M. D. Anderson Cancer Center, Pazdur held administrative positions of assistant vice president for academic affairs, associate director of clinical trials administration (Division of Medicine) and director of educational programs (Division of Medicine). Pazdur served on the faculty of Wayne State University, Detroit, Michigan from 1982 to 1988.
Pazdur received his bachelor’s degree from Northwestern University (Evanston, Illinois), his M.D. from Loyola Stritch School of Medicine (Maywood, Illinois), and completed clinical training at Rush-Presbyterian St. Luke’s Medical Center (Chicago, Illinois) and the University of Chicago Hospitals and Clinics.
Pazdur has published more than 400 articles, book chapters and abstracts. In 2015, Fortune magazine named Pazdur as one of the 50 World’s Greatest Leaders. The American Association for Cancer Research recognized Pazdur with its Distinguished Public Service Award (2015) and the American Society of Clinical Oncology recognized him with the Service Recognition Award (2009) and the Public Service Award (2013). In 2015, Pazdur also received the Public Service Leadership Award from the National Coalition for Cancer Survivorship and also the Face of Hope Award from the LUNGevity Foundation. Most recently, in 2016, Pazdur was named to Massachusetts General Hospital Cancer Center’s “The One Hundred” list.
https://virtualtrials.org/dcvax.cfm
SkyLimit2022
Re: HyGro post# 518555
Sunday, October 02, 2022 9:59:12 PM
Post#
518562
of 518594
Thank you for again highlighting the exemplary trial design—compassionate, clinically appropriate, adaptive, and representative of DCVax as an innovative new platform technology.
The trial design and its endpoints were approved by regulators multiple times. Each country or union of nations has its own RA—Canada, Germany, U.S. and the union of nations U.K. all have RAs. Each approval was a separate and distinct RA approval.
Beyond approval by multiple RAs, the trial design was approved multiple times by the FDA—the crossover design, for example, was approved twice by FDA because there was a trial halt, and then the trial was approved to resume with the same crossover design it previously had.
The MHRA in U.K. approved the trial design and its endpoints twice—once for the adult trial and now again for the pediatric trials:
On August 17, the Company received final approval of the Pediatric Investigation Plan (PIP) from the MHRA. The final regulatory approval of the PIP must be obtained before a sponsor may submit a Marketing Authorization Application (MAA) for approval to commercialize the new medicine for adult patients. The Company’s approved PIP includes a deferral under which the pediatric trials are anticipated to be undertaken after an MAA application has been submitted.
Patients will be treated with DCVax-L on the same treatment schedule as in the Company’s Phase III trial in adult glioblastoma patients.
The primary endpoint for each of the 2 pediatric trials will be overall survival, determined by comparing the survival of DCVax-L treated patients to matched contemporaneous external controls. The external controls will be identified using the same methodology as was used to pre-specify the external controls in the Statistical Analysis Plan for the Company’s Phase III trial in adult patients.
https://virtualtrials.org/dcvax.cfm
https://www.kcl.ac.uk/people/keyoumars-ashkan
https://nwbio.com/press-releases/
More recent news and events:
https://m.youtube.com/watch?v=h_tev1qm1ZE&feature=youtu.be
Dr. Ashkan, a world-renowned clinical trial expert and an advisor to the U.K. government, presents DCVax P3 data.
https://soc-neuro-onc.org/
Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial Plenary Abstract Presenter: Linda M. M. Liau, MD PhD
- University of California, Los Angeles
https://youtu.be/Oq39FFUwKug
UCLA Presentaion
DCVax is discussed beginning at minute 40, to focus on Keytruda (pembrolizumab) plus DCVax in combo at UCLA, skip to minute 45:40
Other Relevant Links:
https://www.kcl.ac.uk/people/keyoumars-ashkan
https://www.liverpool.ac.uk/systems-molecular-and-integrative-biology/staff/michael-jenkinson/
https://www.fda.gov/science-research/advancing-regulatory-science/fda-nih-joint-leadership-council-charter
https://connect.uclahealth.org/2021/03/22/ucla-received-590-million-in-nih-funding-second-highest-total-for-academic-medical-centers-in-2020/
https://virtualtrials.org/dcvax.cfm
https://www.annalsofoncology.org/article/S0923-7534(22)00006-0/fulltext
SkyLimit2022
Re: HyGro post# 518555
Sunday, October 02, 2022 10:03:48 PM
Post#
518563
of 518594
Dubious you say? Your postings would be less dubious if you included this disclosure about your investment in NovoCure:
There are still bigger losers namely the buy and hold shareholders who support DCVax-L with our wallets.
Excellent post, in the passage of time some key and positive factors are forgot or overlooked.
NW Bio’s Phase III Trial With DCVax®-L For Brain Cancer “Adopted” As A National Priority Trial In UK
Cred54675419C's avatar
c red @Cred54675419C
1h
Replying to @TodosInvestor @FlemmingBruce @WayneLee1983
The UK government has set a goal of making the UK a world leading innovator in medicines.
FlemmingBruce's avatar
???? The Danish Dude ???? (Madam/Your highness)
@FlemmingBruce
Replying to @Cred54675419C @TodosInvestor @WayneLee1983
Great info @Cred54675419C ??
The NIHR maintains a “portfolio” of clinical trials that have
been “adopted” as high priorities for the UK. In order to be
selected for the NIHR Portfolio, a proposed clinical trial must go
through multiple layers of review and evaluation. The
evaluation includes the potential significance of the new medical
technology being tested, the quality of the trial design, the
feasibility of the trial, and numerous other factors.
Trials that are selected (“adopted”) for inclusion in the NIHR Portfolio are monitored closely by
the NIHR and the trial sites receive several types of financial and operational support. For
example, the NIHR provides resources and funding for additional staff (e.g., nurses) at the trial
sites to help accelerate the trial. The NIHR also oversees the performance of the sites, and
imposes penalties on the sites for shortfalls such as lags in enrollment.
“We understand that it is relatively rare for a small biotech company to have its clinical trial
‘adopted’ into the NIHR portfolio, especially a Phase III trial,” noted Linda Powers, CEO of NW
Bio. “This important validation of our trial is an exciting development, and the extra resources
and support from the NIHR to the trial sites will be very helpful in accelerating our trial.
https://nwbio.com/nw-bios-phase-iii-trial-with-dcvax-l-for-brain-cancer-adopted-as-a-national-priority-trial-in-uk-2/
Great summary TDD !
Thank you.
GLTU
Replying to
@FlemmingBruce
Comment 3:
Comment 3:
— 🇩🇰 The Danish Dude 🇩🇰 (@FlemmingBruce) October 2, 2022
On Novocures Optune.
Don't like it. Don't understand it. Lot of us don't believe it works. Lot of problems with the clinical trial. pic.twitter.com/vkxmxLaXwT
???? The Danish Dude ???? (Madam/Your highness) $NWBO
@FlemmingBruce
$NWBO
What did Linda Liau say in an interview, 2 years ago?
Comment 1:
What did Linda Liau say in an interview, 2 years ago?
Comment 1:
DONE. Flaskworks has managed to do, what Liau means is lacking.https://t.co/4wzzL2rqTB pic.twitter.com/bCZS8JoXhB
DONE. Flaskworks has managed to do, what Liau means is lacking.
https://billmalloy.info/qa-with-linda-liau/
Mav,
I believe that revenue is highly overrated, anticipation of future growth and revenue is far more important. As you probably know, I'm an investor in IMGN essentially since it's been public, I've watched SGEN grow to many times the market cap of IMGN but still believe IMGN the better investment. SGEN has more approved, but has had very few profitable quarters. Merck did have the sense not to overpay for SGEN, as had been anticipated, but their market cap remains a huge multiple of IMGN's. I believe IMGN's approval of MIRV will make a dent in this, but they'll need a few more drugs to be approved to approach SGEN's market cap, I think it will take a few years, but it will happen.
With a little positive news on DCVax's being the new paradigm in the treatment of cancer I believe we'll see prices between at least $5 and well into double digits. Once shareholders authorize more share whether we get an equity partner or not it won't take that many share to cover operations and clinical trial growth while revenue is growing. Bringing in $100 million is a big deal when you're trading for under $1, it's not so much when you're trading for over $10. While I'd hope they get that equity partnership, but if not as long as the news is what we believe it to be, it won't be a problem.
Gary
A lot of us that bought from $3 up to $12 also backed up the truck between $0.14-$0.50.
I had reduced my average cost to about $0.68 but since I’ve continued adding whenever I have loose change I have raised the average to about $0.75 now.
I regret limiting the buying at $0.14 because of perceived level of risk.
Most of the risks have since been taken out, but hindsight is 20/20
Gary, I have been in this for 7 odd years now. I am a bit fortunate that I sold a little over 50% of my personal investment in NWBO this spring. I am playing with house money at this point and yet I am frustrated given the opportunity cost during these years. I can’t imagine what it must be like for folks that bought a ton 8-9 years ago when NWBO was trading over $5. They got diluted like hell.
I am convinced that 2023 will be disappointing from a revenue perspective. So we ain’t going anywhere for a while unless there is a major partnership announcement soon and that seems unlikely at the rate they are diluting us.
that would be interesting ;)
There was never a dubious NWBO Phase 3 trial. NWBO is on the right path and that is all that matters.
Once again, NWBO SEC filings are as clear as day, but perhaps you are in a dark place unable to read the true NWBO SEC filings. Recommend a new pair of glasses.
NWBO's SEC filings are all in order and in accordance with the SEC regulation standards.
No, not at all, I mean the real OS data, case closed since the OS data is valid and real.
HyGro,
You appear to be reading the risk section of SEC filings for NWBO like there is a boogeyman trying to attack investors then post here warning us that we will be attacked too. I am very certain that almost all the longs on this board have moved well along from that particular stage of human development and are quite aware of the risks here and of getting out of bed in the morning and heading out. It’s an apple not the sky or in Poor Man’s case it might just be a pigeon ; ). Best wishes.
Followers
|
1638
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
720615
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators flipper44 sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |